Evaluating Diagnostic Accuracy of Saliva Sampling Methods for Severe Acute Respiratory Syndrome Coronavirus 2 Reveals Differential Sensitivity and Association with Viral Load.


Journal

The Journal of molecular diagnostics : JMD
ISSN: 1943-7811
Titre abrégé: J Mol Diagn
Pays: United States
ID NLM: 100893612

Informations de publication

Date de publication:
10 2021
Historique:
received: 06 01 2021
revised: 21 06 2021
accepted: 07 07 2021
pubmed: 7 8 2021
medline: 16 10 2021
entrez: 6 8 2021
Statut: ppublish

Résumé

Nasopharyngeal swabs are considered the preferential collection method for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) diagnostics. Less invasive and simpler alternative sampling procedures, such as saliva collection, are desirable. We compared saliva specimens and nasopharyngeal (NP) swabs with respect to sensitivity in detecting SARS-CoV-2. A nasopharyngeal and two saliva specimens (collected by spitting or oral swabbing) were obtained from >2500 individuals. All samples were tested by RT-qPCR, detecting RNA of SARS-CoV-2. The test sensitivity was compared on the two saliva collections with the nasopharyngeal specimen for all subjects and stratified by symptom status and viral load. Of the 2850 patients for whom all three samples were available, 105 were positive on NP swab, whereas 32 and 23 were also positive on saliva spitting and saliva swabbing samples, respectively. The sensitivity of the RT-qPCR to detect SARS-CoV-2 among NP-positive patients was 30.5% (95% CI, 1.9%-40.2%) for saliva spitting and 21.9% (95% CI, 14.4%-31.0%) for saliva swabbing. However, when focusing on subjects with medium to high viral load, sensitivity on saliva increased substantially: 93.9% (95% CI, 79.8%-99.3%) and 76.9% (95% CI, 56.4%-91.0%) for spitting and swabbing, respectively, regardless of symptomatic status. Our results suggest that saliva cannot readily replace nasopharyngeal sampling for SARS-CoV-2 diagnostics but may enable identification of the most contagious cases with medium to high viral loads.

Identifiants

pubmed: 34358676
pii: S1525-1578(21)00241-5
doi: 10.1016/j.jmoldx.2021.07.017
pmc: PMC8330145
pii:
doi:

Types de publication

Evaluation Study Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1249-1258

Informations de copyright

Copyright © 2021 Association for Molecular Pathology and American Society for Investigative Pathology. Published by Elsevier Inc. All rights reserved.

Références

Sci Rep. 2022 Apr 22;12(1):6603
pubmed: 35459775
Clin Infect Dis. 2021 May 4;72(9):e352-e356
pubmed: 32761244
Nat Commun. 2021 Jan 11;12(1):267
pubmed: 33431879
N Engl J Med. 2020 Sep 24;383(13):1283-1286
pubmed: 32857487
BMC Infect Dis. 2013 Jun 20;13:281
pubmed: 23786598
J Clin Microbiol. 2020 Jul 23;58(8):
pubmed: 32317257
Clin Microbiol Infect. 2021 Feb;27(2):285.e1-285.e4
pubmed: 32422408
PLoS One. 2011;6(6):e21610
pubmed: 21738731
BMJ Open. 2016 Nov 14;6(11):e012799
pubmed: 28137831
Stat Med. 2003 Apr 30;22(8):1217-33
pubmed: 12687652
Clin Infect Dis. 2008 Apr 1;46(7):e61-4
pubmed: 18444806
Euro Surveill. 2020 Jan;25(3):
pubmed: 31992387
J Clin Microbiol. 2016 Dec 28;55(1):226-233
pubmed: 27807150
J Infect. 2020 Aug;81(2):e145-e147
pubmed: 32504740
J Clin Virol. 2020 Sep;130:104567
pubmed: 32750665
JAMA Intern Med. 2021 Mar 1;181(3):353-360
pubmed: 33449069
J Infect. 2020 Jul;81(1):e45-e50
pubmed: 32298676

Auteurs

Pieter Mestdagh (P)

Biogazelle, Zwijnaarde, Belgium; Department of Biomolecular Medicine, Ghent University, Ghent, Belgium.

Michel Gillard (M)

UCB, Braine-l'Alleud, Belgium.

Sharonjit K Dhillon (SK)

Unit of Cancer Epidemiology, Belgian Cancer Centre, Sciensano, Brussels, Belgium.

Jean-Paul Pirnay (JP)

Laboratory for Molecular and Cellular Technology, Queen Astrid Military Hospital, Brussels, Belgium.

Jeroen Poels (J)

Federal Agency for Medicines and Health Products, Brussels, Belgium.

Jan Hellemans (J)

Biogazelle, Zwijnaarde, Belgium.

Veronik Hutse (V)

Service of Viral Diseases, Operational Directorate Infectious Diseases in Humans, Sciensano, Brussels, Belgium.

Celine Vermeiren (C)

UCB, Braine-l'Alleud, Belgium.

Maxime Boutier (M)

UCB, Braine-l'Alleud, Belgium.

Veerle De Wever (V)

UCB, Braine-l'Alleud, Belgium.

Patrick Soentjens (P)

Center for Infectious Diseases, Queen Astrid Military Hospital, Brussels, Belgium; Department of Clinical Sciences, Institute of Tropical Medicine, Antwerp, Belgium.

Sarah Djebara (S)

Center for Infectious Diseases, Queen Astrid Military Hospital, Brussels, Belgium.

Hugues Malonne (H)

Federal Agency for Medicines and Health Products, Brussels, Belgium; Unit of Pharmacology, Pharmacotherapy and Pharmaceutical Care, Faculty of Pharmacy, Université Libre de Bruxelles, Brussels, Belgium; Department of Biomedical Sciences, Namur Research Institute for Life Sciences, University of Namur, Namur, Belgium.

Emmanuel André (E)

Laboratory of Clinical Bacteriology and Mycology, KU Leuven, Leuven, Belgium.

Marc Arbyn (M)

Unit of Cancer Epidemiology, Belgian Cancer Centre, Sciensano, Brussels, Belgium.

John Smeraglia (J)

UCB, Braine-l'Alleud, Belgium.

Jo Vandesompele (J)

Biogazelle, Zwijnaarde, Belgium; Department of Biomolecular Medicine, Ghent University, Ghent, Belgium. Electronic address: jo.vandesompele@biogazelle.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH